Microcap Ledger

Tickers · $ICU

SeaStar Medical Holding Corp $ICU

By Microcap Ledger desk · CIK 0001831868

Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange
Nasdaq Capital Market
Sector
Surgical & Medical Instruments & Apparatus
Headquarters
Denver, CO
Fiscal year end
December 31
Shares outstanding
4,406,841 [10-Q 2026-08-12]
as of 2026-08-05

Sources: [10-K 2026-03-25]

What the company doesAI summary of filing

SeaStar Medical is a commercial-stage healthcare company that develops the Selective Cytopheretic Device (SCD), an extracorporeal medical device designed to treat hyperinflammatory conditions in critically ill patients. The company received FDA approval in February 2024 for QUELIMMUNE, its first product for pediatric patients with acute kidney injury due to sepsis, and began commercial shipments in July 2024. SeaStar is currently conducting a pivotal clinical trial (NEUTRALIZE-AKI) in adult acute kidney injury patients and feasibility studies in cardiorenal syndrome patients. The company generates revenue from product sales and is pursuing multiple indications across acute and chronic inflammatory diseases. [10-K 2026-03-25]

Segments: QUELIMMUNE (pediatric acute kidney injury), NEUTRALIZE-AKI (adult acute kidney injury), Cardiorenal syndrome (CRS), End-stage renal disease (ESRD) chronic hemodialysis

Financial health

From XBRL company facts (USD)
PeriodRevenueNet incomeOperating cash flowCashFiling
6 months to Jun 2026$1.11M−$7.25M −$5.75M$6.96M[10-Q 2026-08-12]
FY ended Dec 2025$1.23M−$12.15M −$13.60M$11.98M[10-K 2026-03-25]
FY ended Dec 2024$135.0K−$24.83M −$16.01M$1.82M[10-K 2026-03-25]
Quarterly cash burn
−$2.88M
Cash runway Estimate
~7.3 months

Estimate: cash at the end of the period (6 months to Jun 2026) divided by the average monthly operating cash outflow over that period. Ignores any cash raised or spent since, and any financing.

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
DateShares outstandingFiling
2024-11-064,463,148[10-Q 2024-11-13]
2025-02-288,721,036[10-K 2025-03-27]
2025-05-1210,563,748[10-Q 2025-05-14]
2025-08-0627,914,596[10-Q 2025-08-13]
2025-11-0736,047,134[10-Q 2025-11-13]
2026-03-243,993,719[10-K 2026-03-25]
2026-05-073,997,002[10-Q 2026-05-13]
2026-08-054,406,841[10-Q 2026-08-12]
Shelf registration
S-1 filed 2026-04-28; declared effective 2026-05-11 [S-1 2026-04-28]

Listing status

Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-08-06. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

DateEventDetailsDeadlineFiling
2025-08-068-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2025-08-06]
2025-01-318-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2025-01-31]
2024-12-268-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2024-12-26]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
DateInsiderTypeSharesPriceFiling
2026-08-18Messinger Michaelbuy750$3.27[4 2026-08-19]
2026-07-01Schlorff Ericgrant10,288—[4 2026-07-02]
2026-07-01Chung Kevingrant7,202—[4 2026-07-02]
2026-07-01Vincent Bernadette Ngrant4,000—[4 2026-07-02]
2026-07-01Neuman Johngrant4,000—[4 2026-07-02]
2026-07-01Van Heel Kennethgrant4,000—[4 2026-07-02]
2026-07-01Baird Jennifer Agrant4,000—[4 2026-07-02]
2026-02-06Van Heel Kennethgrant3,000—[4 2026-02-10]

Catalysts and calendar

Facts as of . Small caps move fast; check the latest filings.